Press Release June 02, 2016

PRESS: Pharma Companies Warn of Regulatory ‘Dead Zone’ With FDA’s Interpretation of BPCIA (Regulatory Affairs Professionals Society)

Robert Cerwinski, a partner in Goodwin's IP Litigation Group, expands on the recent calls on for the FDA to amend its interpretation of the "deemed to be a license" provision of the Biologics Price Competition and Innovation Act of 2010.

Read the full Regulatory Affairs Professionals Society article here.